Kymera Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety reported to be useful for the treatment of cancer.

Biogen Inc. and C4 Therapeutics Inc. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising a degradation signaling moiety such as E3 ubiquitin ligase-binding moiety covalently linked to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of leukemia and lymphoma, multiple sclerosis, atopic dermatitis, rheumatoid arthritis and systemic lupus erythematosus.

Jbklab Co. Ltd. has synthesized compounds reported to be useful for the treatment of cancer.

Constellation Pharmaceuticals Inc. has presented three-prime repair exonuclease (TREX) inhibitors reported to be useful for the treatment of cancer.

Texas A&M University System has discovered 3C-like proteinase (3CLpro) (SARS-CoV-2; COVID-19 virus) and cytochrome P450 3A4 (CYP3A4) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.

Merck Sharp & Dohme Corp. has described 3-oxopiperazine carboxamide derivatives acting as sodium channel protein type 10 subunit alpha (Nav1.8) blockers reported to be useful for the treatment of cough, pruritus, acute and neuropathic pain.

Taisho Pharmaceutical Co. Ltd. has synthesized sulfonamide-containing peptides acting as MMP-7 (matrilysin) inhibitors reported to be useful for the treatment of cancer.

Scientists at the University of Turin and the University of Pisa have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, neurodegeneration, cancer, cardiovascular disorders, and autoimmune and metabolic disease.

Katholieke Universiteit Leuven has patented compounds reported to useful for the treatment of epilepsy.